Table 2 Predicted canonical pathways affected in GOT1 tumors after 177Lu-octreotate therapy with priming
Ingenuity Canonical Pathways | p | Targets from transcriptional data | |
|---|---|---|---|
1 day | |||
Systemic lupus erythematosus signaling | 1.3 × 10−4 | ↓RNU1-3, ↓RNU1-5, ↓RNU1A3 | |
► | PI3K/AKT signaling | 3.4 × 10−3 | ↑PPP2R2B, ↑CDKN1A, ↑GDF15 |
Taurine biosynthesis | 5.0 × 10−3 | ↓CDO1 | |
► | Role of CHK proteins in cell cycle checkpoint control | 8.3 × 10−3 | ↑PPP2R2B, ↑CDKN1A |
L-cysteine degradation | 1.0 × 10−2 | ↓CDO1 | |
3 days | |||
p53 signaling | 3.2 × 10−5 | ↑GADD45A, ↑TNFRSF10B, ↑CDKN1A, ↑TIGAR, ↑BAX | |
GADD45 signaling | 3.2 × 10−5 | ↑CCND3, ↑GADD45A, ↑CDKN1A | |
► | Unfolded protein response | 7.1 × 10−4 | ↑DDIT3, ↓INSIG1, ↑HSPH1 |
Cholesterol biosynthesis | 8.1 × 10−4 | ↓FDFT1, ↓MSMO1 | |
► | Death receptor signaling | 3.6 × 10−2 | ↑ACTA2, ↑TNFRSF10B |
7 days | |||
Systemic lupus erythematosus signaling | 1.3 × 10−4 | ↓RNU1-3, ↓RNU1-5, ↓RNU4-2, ↓RNU4-1 | |
LXR/RXR activation | 1.3 × 10−3 | ↓FDFT1, ↑APOE, ↓LDLR, ↑ABCA1 | |
► | Epoxysqualene biosynthesis | 7.8 × 10−3 | ↓FDFT1 |
► | p53 signaling | 9.3 × 10−3 | ↑TNFRSF10B, ↑CDKN1A, ↑SERPINE2 |
► | Serotonin and melatonin biosynthesis | 2.0 × 10−2 | ↑TPH1 |
41 days | |||
► | Role of Oct4 in mammalian embryonic stem cell pluripotency | 1.6 × 10−3 | ↓SOX2, ↓NR2F2 |
► | Lactose degradation | 5.3 × 10−3 | ↑GBA3 |
► | CDK5 signaling | 7.1 × 10−3 | ↓EGR1, ↑PPP2R2C |
Embryonic stem cell differentiation into cardiac lineages | 1.3 × 10−2 | ↓SOX2 | |
► | Wnt/β-catenin signaling | 2.0 × 10−2 | ↓SOX2, ↑PPP2R2C |